Testosterone Deficiency in Men

Fatigue, reduced sexual desire, declining physical performance or erectile difficulties: many men experience changes during their lives that they initially attribute to ageing, stress or professional demands. Sometimes, however, testosterone deficiency may be responsible.

Testosterone is the principal male sex hormone. It influences not only sexual function but also muscle mass, bone metabolism, red blood cell production and numerous other physiological processes. A medically significant testosterone deficiency, also known as male hypogonadism, can substantially affect quality of life. However, fatigue or reduced physical performance does not automatically indicate low testosterone levels.

The key question is therefore whether a genuine hormonal deficiency is present, whether it explains the symptoms and whether targeted treatment is appropriate.

What does testosterone do in the male body?

Testosterone is primarily produced by the Leydig cells in the testes. Its production is controlled by a hormonal regulatory system involving the hypothalamus, pituitary gland and testes.

Testosterone performs several essential functions:

  • Sexual health: It influences sexual desire (libido) and contributes to normal sexual function.
  • Muscles: It supports the development and maintenance of muscle mass and strength.
  • Bones: It is important for maintaining bone mineral density.
  • Blood production: It stimulates the production of red blood cells.
  • Body composition: It influences the distribution of muscle and fat tissue.
  • Sexual development: It is essential for the development and maintenance of male sexual characteristics.

Testosterone levels fluctuate throughout the day and are influenced by sleep, body weight, metabolism and various medical conditions. Testosterone concentrations may gradually decline with increasing age. In healthy men, however, this reduction is often relatively small. Low testosterone should therefore not automatically be regarded as an inevitable consequence of ageing.

What symptoms may indicate testosterone deficiency?

Symptoms can vary considerably. Some are relatively characteristic, while others occur in numerous unrelated medical conditions.

1. Changes in sexual function

Important signs include:

  • reduced sexual desire (loss of libido)
  • fewer spontaneous or morning erections
  • erectile dysfunction
  • reduced sexual arousal
  • changes in sexual wellbeing

Sexual symptoms are among the more specific indicators of testosterone deficiency. However, erectile dysfunction may also result from vascular disease, diabetes, medication or psychological factors (see Erectile dysfunction).

2. Physical changes

Possible physical manifestations include:

  • reduced muscle mass and strength
  • increased body fat
  • reduced physical endurance
  • reduced bone mineral density or osteoporosis
  • occasionally anaemia
  • reduced body hair in cases of severe or longstanding deficiency

3. General symptoms

Some men also experience:

  • fatigue and exhaustion
  • reduced motivation
  • difficulty concentrating
  • low mood
  • sleep disturbances
  • reduced overall performance

These symptoms are nonspecific. Sleep deprivation, depression, thyroid disorders, chronic stress and various other medical conditions may cause similar complaints.

Testosterone deficiency can therefore never be diagnosed on the basis of symptoms alone.

What causes testosterone deficiency?

Three important forms are generally distinguished.

1. Primary hypogonadism: impaired testicular function

In primary hypogonadism, the testes are unable to produce sufficient testosterone despite hormonal stimulation from the pituitary gland.

Possible causes include:

  • congenital conditions such as Klinefelter syndrome
  • previous testicular inflammation
  • testicular injuries or surgery
  • chemotherapy or radiotherapy
  • other disorders affecting testicular tissue

Luteinising hormone (LH) and often follicle-stimulating hormone (FSH) are typically elevated.

2. Secondary hypogonadism: impaired hormonal regulation

In secondary hypogonadism, the underlying problem involves the hypothalamus or pituitary gland. The testes do not receive sufficient hormonal stimulation to produce adequate testosterone.

Possible causes include:

  • pituitary disorders
  • elevated prolactin levels
  • certain congenital hormonal conditions
  • medications, particularly opioids or glucocorticoids
  • previous use of anabolic steroids
  • severe systemic illnesses

LH and FSH levels are frequently low or inappropriately normal despite reduced testosterone concentrations.

3. Functional hypogonadism

Functional hypogonadism is particularly relevant in adult men. Hormonal regulation is impaired by associated diseases or other contributing factors, without necessarily involving permanent structural damage to the testes or pituitary gland.

Common contributing factors include:

  • obesity, particularly excess abdominal fat
  • metabolic syndrome
  • type 2 diabetes
  • sleep disorders
  • chronic illnesses
  • certain medications

In functional hypogonadism, testosterone levels may improve when the underlying conditions are successfully treated. For this reason, a low testosterone result should not automatically lead to hormone replacement therapy.

How is testosterone deficiency diagnosed?

Diagnosis requires both compatible clinical symptoms and repeatedly confirmed low testosterone concentrations.

Timing of blood sampling matters

Testosterone follows a daily rhythm. Blood samples should therefore preferably be taken in the morning, between 7 and 10 a.m., and after fasting. A single low result is insufficient to establish the diagnosis. The measurement should be repeated on a different day under comparable conditions. Acute illness, inadequate sleep and certain medications can temporarily influence testosterone levels.

At what level is testosterone considered low?

The European Association of Urology (EAU) guidelines use a total testosterone concentration of approximately 12 nmol/L (about 3.5 ng/mL) as an important diagnostic threshold in men with compatible symptoms.

However, 12 nmol/L is not an automatic treatment threshold. Interpretation also depends on symptoms, laboratory methods, age, associated medical conditions and additional biochemical parameters. In borderline cases, or in conditions affecting testosterone-binding proteins, sex hormone-binding globulin (SHBG) should also be measured and free testosterone calculated where appropriate.

Which additional investigations may be necessary?

Depending on the clinical situation, investigations may include:

  • LH and FSH to distinguish primary from secondary hypogonadism
  • prolactin when pituitary dysfunction is suspected
  • SHBG and calculated free testosterone
  • full blood count
  • metabolic parameters such as blood glucose or HbA1c
  • thyroid function tests when clinically indicated
  • PSA testing and prostate assessment before testosterone treatment, according to individual risk

In severe secondary hypogonadism or when pituitary disease is suspected, magnetic resonance imaging (MRI) of the pituitary gland may be required. Not every patient requires all these investigations. Assessment is tailored individually.

When is testosterone therapy appropriate?

Testosterone replacement therapy (TRT) may be appropriate for men with clearly confirmed hypogonadism and corresponding symptoms. The aim is to restore testosterone concentrations to a physiological range and thereby improve symptoms attributable to hormonal deficiency.

However, testosterone treatment is not a general anti-ageing intervention or a substitute for a healthy lifestyle. In particular, testosterone administration in men with normal hormone levels to improve fitness, muscle growth or general performance is not medically justified.

Before treatment begins, possible causes of deficiency, existing medical conditions and individual circumstances must be considered.

A particularly important question is whether the patient wishes to have children now or in the future.

What forms of testosterone replacement therapy are available?

Testosterone is a prescription-only medicine. It is prescribed only after a medical examination. We decide individually which form and which dose are suitable.

1. Testosterone gel

Testosterone gel is applied to the skin every day. The active substance is absorbed through the skin into the bloodstream.

Advantages:

  • relatively stable daily hormone delivery when used correctly
  • individual dose adjustment
  • hormone administration can be stopped relatively quickly

Disadvantages:

  • daily application is required
  • absorption may vary
  • risk of unintentional transfer to other people through skin contact

Appropriate hygiene and precautions must be followed after application.

2. Testosterone injections

Testosterone can also be administered by intramuscular injection. Long-acting formulations provide testosterone over several weeks.

Advantages:

  • no daily application
  • longer intervals between treatments
  • good effectiveness with appropriate dosing

Disadvantages:

  • regular injections are required
  • individual variations in testosterone concentrations
  • less flexibility for rapid dose adjustment or discontinuation with long-acting preparations

The most appropriate treatment depends on hormone levels, tolerability, associated medical conditions and personal preferences.

What improvements can testosterone therapy provide?

In men with confirmed testosterone deficiency, appropriately administered replacement therapy may improve several symptoms.

Sexual desire and sexual function

Scientific evidence is particularly strong for improvements in sexual desire in men with hypogonadism. Sexual activity and overall sexual satisfaction may also improve.

The effect on erectile dysfunction is generally more modest. As erectile difficulties frequently have additional vascular or metabolic causes, specific treatment with PDE-5 inhibitors such as tadalafil or sildenafil may still be necessary.

Body composition and muscles

Testosterone replacement therapy can increase lean body mass and reduce body fat. However, these changes do not automatically translate into improved physical performance. Regular resistance training, balanced nutrition and sufficient physical activity remain essential.

Bone health

Testosterone contributes to maintaining bone mineral density. In men with significant hypogonadism, treatment may improve bone density. However, reliable protection against bone fractures through testosterone treatment has not been established.

Mood, energy and physical performance

Some men report improvements in mood or general wellbeing during treatment. Scientific findings in this area are less consistent than those relating to sexual symptoms. In particular, severe fatigue or exhaustion does not necessarily improve with testosterone replacement.

Testosterone therapy and fertility: an important consideration

Testosterone replacement therapy can substantially suppress the body's natural sperm production. External testosterone reduces hormonal stimulation of the testes through LH and FSH. Consequently, sperm production may decrease markedly or temporarily stop altogether.

Men who are currently trying to conceive should therefore not receive conventional testosterone replacement therapy.

In certain forms of secondary hypogonadism, alternative hormonal treatments may be considered, for example human chorionic gonadotropin (hCG), sometimes combined with FSH. These treatments can stimulate testicular function and sperm production. Treatment selection requires a dedicated andrological assessment (see also Unfulfilled desire to have children).

What are the risks and side effects of testosterone therapy?

When correctly prescribed, testosterone replacement therapy can be effective and reasonably safe in appropriately selected patients. Nevertheless, careful assessment and regular monitoring are essential.

1. Increased haematocrit

Testosterone stimulates red blood cell production. This can increase haemoglobin and haematocrit levels. A marked increase may raise the risk of complications. If haematocrit exceeds 54%, treatment must be adjusted or temporarily discontinued, and the underlying cause investigated.

2. Prostate health and PSA levels

Testosterone affects prostate tissue and may cause PSA levels to rise. Individual prostate cancer risk must therefore be considered before treatment begins.

Existing locally advanced or metastatic prostate cancer is a contraindication. The situation is more nuanced in men who have successfully completed treatment for localised prostate cancer and requires particularly careful individual assessment (see Prostate cancer).

Physiological testosterone replacement in appropriately selected men has not been shown to cause a general increase in prostate cancer risk. Nevertheless, appropriate baseline assessment and follow-up are required.

3. Cardiovascular disease

The cardiovascular safety of testosterone therapy has been investigated in large clinical trials. The TRAVERSE trial, involving more than 5,200 men, demonstrated that testosterone therapy was non-inferior to placebo with regard to major cardiovascular events, including myocardial infarction, stroke and cardiovascular death.

However, certain adverse events occurred more frequently in the testosterone group, including atrial fibrillation, pulmonary embolism and acute kidney injury.

These findings do not support categorising testosterone therapy as universally harmful to cardiovascular health, but they do not establish unrestricted safety either. Individual benefit–risk assessment is essential in men with cardiovascular disease.

4. Other potential side effects

These include:

  • acne and increased skin oiliness
  • breast tissue changes
  • reduced testicular size
  • suppression of sperm production
  • increased haematocrit
  • adverse effects associated with the particular formulation

In certain conditions, such as uncontrolled heart failure, markedly elevated haematocrit or severe untreated obstructive sleep apnoea, testosterone treatment is not indicated or should be deferred.

What monitoring is required during treatment?

Testosterone replacement therapy should always be medically supervised. Important follow-up assessments include:

  • testosterone concentrations
  • haemoglobin and haematocrit
  • PSA according to age and individual prostate cancer risk
  • symptoms and clinical response
  • potential adverse effects
  • general health and cardiovascular risk factors

According to European recommendations, testosterone and haematocrit are generally monitored at three, six and twelve months, followed by at least annual assessments. More frequent monitoring may be necessary depending on individual risk. The timing of testosterone measurements must also take account of the formulation and its pharmacokinetic profile.

The objective is not to achieve the highest possible testosterone concentration, but a physiological level associated with meaningful clinical benefit.

Can testosterone levels be improved without medication?

Lifestyle changes can play a major role in functional hypogonadism. Important measures include:

  • Weight loss: In men with overweight or obesity, sustained weight reduction may increase testosterone concentrations.
  • Regular exercise: Physical activity supports metabolic health, muscle preservation and general physical performance.
  • Adequate sleep: Sleep disorders and chronic sleep deprivation may impair hormonal regulation.
  • Treatment of associated conditions: Effective management of diabetes, metabolic syndrome and other chronic illnesses can improve hormonal health.
  • Medication review: Certain medications can affect endogenous testosterone production.

So-called testosterone boosters advertised online frequently lack convincing scientific evidence. In organic hypogonadism, however, lifestyle changes alone are usually insufficient to restore normal hormone production.

When should testosterone levels be checked?

A urological and andrological assessment may be appropriate if the following symptoms persist:

  • markedly reduced sexual desire
  • fewer morning erections
  • erectile dysfunction
  • unexplained loss of muscle mass or physical performance
  • reduced bone mineral density or osteoporosis
  • unexplained anaemia
  • several symptoms suggestive of testosterone deficiency occurring together

Testing may also be appropriate in certain medical conditions or following treatments that can impair testicular function. Routine testosterone screening in all asymptomatic men is not recommended.

Conclusion: recognising and treating testosterone deficiency

Testosterone deficiency can significantly affect sexual function, physical health and quality of life. However, it is essential to distinguish genuine hormonal deficiency from other conditions causing similar symptoms. Diagnosis is based on characteristic symptoms and at least two appropriately performed hormone measurements.

When hypogonadism is confirmed, individualised testosterone replacement therapy may be effective. At the same time, potential risks, associated medical conditions and particularly fertility plans must be considered.

Dr. med. Maximilian Thomas, FMH specialist in urology, FEBU
Not every man experiencing fatigue needs testosterone. But every man with confirmed testosterone deficiency deserves a thorough assessment and treatment tailored to his individual needs.
Dr. med. Maximilian Thomas

Men's health at Urologie Zentrum Hergiswil

The assessment and treatment of male hormonal disorders are important aspects of modern andrology. At Urologie Zentrum Hergiswil, we provide individual diagnostic assessment for suspected testosterone deficiency and specialist-supervised treatment for confirmed hypogonadism. Our services include hormonal evaluation, advice on different treatment options and the necessary medical follow-up.

Our aim is to address symptoms effectively and achieve lasting improvements in quality of life, based on current scientific evidence and each patient's individual circumstances.

Scientific references

  1. EAU Guidelines on Sexual and Reproductive Health, 2026. Male Hypogonadism. Basis for diagnosis, treatment and monitoring.
  2. Corona G et al. EAU Guidelines on Sexual and Reproductive Health: Recommendations for Measurement and Biochemical Confirmation of Hypogonadism. European Urology Focus. 2026.
  3. Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE trial). New England Journal of Medicine. 2023.
  4. Snyder PJ et al. Testosterone Treatment and Fractures in Men with Hypogonadism. New England Journal of Medicine. 2024.
  5. Endocrine Society Clinical Practice Guideline. Testosterone Therapy for Hypogonadism.

Next step

Call to arrange an appointment · 041 630 00 10
Reachable by phoneMon–Fri 08:30–12:00 / 13:30–16:30
All contact options